Antidepressants and QTc prolongation

Journal of Psychiatry and Neuroscience

Volumn 38, Issue 2, 2013, Pages E5-

  Lam, Raymond W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; PSYCHOTROPIC AGENT;

ADULT; CORONARY ARTERY DISEASE; DEPRESSION; DRUG MONITORING; HUMAN; MALE; NOTE; QT PROLONGATION; RECOMMENDED DRUG DOSE; CHEMICALLY INDUCED; COMPLICATION; DEPRESSIVE DISORDER; FEMALE; LONG QT SYNDROME; RISK FACTOR; SEX DIFFERENCE; TORSADES DE POINTES;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER; FEMALE; HUMANS; LONG QT SYNDROME; MALE; RISK FACTORS; SEX FACTORS; TORSADES DE POINTES;

EID: 84874292870     PISSN: 11804882     EISSN: 14882434     Source Type: Journal    
DOI: 10.1503/jpn.120256     Document Type: Note

References (9)

1. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010; 5:97-104.
2. Heist EK, Ruskin JN. Drug-induced proarrythmia and use of QTc prolonging agents: clues for clinicians. Heart Rhythm 2005;2:S1-8.
3. Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005;20:243-51.
4. Barnes BJ, Hollands J M. Drug-induced arrhythmias. Crit Care Med 2010;38 (Suppl):S188-97.
5. Drug lists by risk groups: drugs that prolong the QT interval and/or induce Torsades de Pointes. In: CredibleMeds [a website of AZCERT, Inc.]. Available: www.azcert.org/medical-pros/drug-lists/drug-lists.cfm (accessed 2012 Apr. 11).
6. Wenzel-Seifert K, Wittmann M, Haen E. Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry 2010; 43:279-81.
7. Vieweg WV, Hasnain M, Howland RH, et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? Am J Med 2012;125:859-68.
8. Howland RH. A critical evaluation of the cardiac toxicity of citalopram: part 1. J Psychosoc Nurs Ment Health Serv 2011; 49:13-6.
9. Hanash JA, Hansen BH, Hansen JF, et al. Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: Results From the DEpression in patients with Coronary ARtery Disease (DECARD) Trial. J Cardiovasc Pharmacol 2012;60:397-405.